Severin Schwan, Roche Group CEO (AP Images)

Roche re­gains pre-pan­dem­ic sales foot­ing, high­lights burst­ing pipeline — with one key fail­ure

While many phar­ma for­tunes are tied to Covid-19 pan­dem­ic peaks and val­leys, Roche’s con­nec­tions are more com­pli­cat­ed than most, born out in its 2021 fi­nan­cial re­port­ing.

On one hand, its al­ways top-of-mind di­ag­nos­tics busi­ness, bol­stered by anti­gen and PCR test­ing, saw soar­ing sales, up 29% to CHF $17.76 bil­lion ($19.3B) in 2021. On the oth­er hand, its phar­ma busi­ness — while be­gin­ning to re­bound by year’s end with growth 2% high­er than an­a­lyst ex­pec­ta­tions in Q4 — moved up just 3% in 2021 end­ing with sales of CHF $45.04 bil­lion ($49 bil­lion).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.